ARCHIVES

IOM Committee Focuses on Studies Needed To Protect Patients On Omics-Based Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 41 | November 4, 2011

Download PDF Visit The Full Archive

Related Articles

Hawaiian Have Highest Cancer Rate In U.S.

April 29, 1983

In Phase II Study, NKTR-102 Shows Objective Response

January 28, 2011

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014

DCT Board reluctantly Okays Resources Contracts Recompetition, $6 of $10 Million Competitively

April 1, 1977

Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase

December 19, 1997

Private Sector Still Valuable To National Cancer Program, ACS Research Chief Says

April 26, 1974